HCA Healthcare (HCA) Gains from Sales and Divestitures (2012 - 2025)

HCA Healthcare (HCA) has 13 years of Gains from Sales and Divestitures data on file, last reported at $717000.0 in Q4 2025.

• Quarterly Gains from Sales and Divestitures rose 12.21% year-over-year to $717000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $717000.0 (up 12.21% YoY) and the FY2025 annual result came in at $717000.0, up 12.21% from the prior year.
• Gains from Sales and Divestitures improved to $717000.0 in Q4 2025 per HCA's latest filing, from $639000.0 in the prior quarter.
• Across five years, Gains from Sales and Divestitures topped out at $992000.0 in Q4 2021 and bottomed at $639000.0 in Q4 2024.
• The 5-year median for Gains from Sales and Divestitures is $717000.0 (2023), against an average of $788600.0.
• The widest annual swing landed in 2021, when Gains from Sales and Divestitures slumped 58.56%; it then advanced 12.21% in 2025.
• Tracing HCA's Gains from Sales and Divestitures over 5 years: stood at $992000.0 in 2021, then fell by 11.49% to $878000.0 in 2022, then slipped by 18.34% to $717000.0 in 2023, then dropped by 10.88% to $639000.0 in 2024, then rose by 12.21% to $717000.0 in 2025.
• Per Business Quant, the three latest HCA Gains from Sales and Divestitures figures stand at $717000.0 (Q4 2025), $639000.0 (Q4 2024), and $717000.0 (Q4 2023).

Peer Comparison